Similarly, apigenin targets the PI3K/Akt and integrin β1-FAK signaling pathways, disrupting tumor survival mechanisms and limiting growth, particularly in treatment-resistant cancers (Tripathi et al., 2024). Here, AKT1 is linked to neoplasm.